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The three international drug control conventions (the drug control system)
  Single Convention on Narcotic Drugs (1961) as amended by the 1972 Protocol Amending the Single 
Convention on Narcotic Drugs
  Convention on Psychotropic Substances (1971)
  Convention against Illicit Traffi  c in Narcotic Drugs and Psychotropic Substances (1988)
The 1961 treaty lists all controlled substances according to their perceived therapeutic value and liability for 
abuse. It also creates the International Narcotics Control Board (INCB) with responsibility to restrict cultivation, 
production, manufacture and use of scheduled drugs to the amount required for medical and scientifi c purposes; 
ensure access to controlled drugs for such purposes; and prevent illicit cultivation, production and traffi  cking. 
The 1972 protocol amending the 1961 Convention incorporates care and treatment of people who use drugs 
into the 1961 Convention. The 1971 treaty brings psychoactive drugs into the control system. The 1988 treaty 
mandates increased international law enforcement and stronger domestic criminal legislation within the national 
legal framework of sovereign states. 
Illicit drugs
The international drug control conventions do not distinguish between licit and illicit drugs. It is the cultivation, 
production, manufacture, export and import of, trade in, possession or use of drugs contrary to the provisions 
of the conventions that can be licit or illicit, but not the substance itself. However, substances categorized in the 
conventions under Schedule IV—‘particularly liable to abuse’ and having no therapeutic value—are essentially 
judged to be illicit for medical and scientifi c purposes. In this paper, ‘illicit drugs’ refers to substances that are subject 
to international control under the drug conventions and are cultivated, produced, manufactured, traffi  cked and/or 
used contrary to the provisions of the conventions.
International drug control institutions
  Commission on Narcotic Drugs (CND): the United Nations (UN) Member State body charged with directing 
international drug policy. The CND is a functional commission of the Economic and Social Council 
(ECOSOC)
  United Nations Offi  ce on Drugs and Crime (UNODC): the secretariat of the CND and a UN programme that 
undertakes the substantive work on drug control
  International Narcotics Control Board: the independent committee created by the 1961 Single Convention 
on Narcotic Drugs to monitor the cultivation, production, manufacture and use of scheduled drugs to the 
amount required for medical and scientifi c purposes
GLOSSARY
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Harm reduction
According to the World Health Organization (WHO), the Joint United Nations Programme on HIV/AIDS (UNAIDS) 
and UNODC, harm reduction refers to policies, programmes and practices that aim primarily to reduce the adverse 
health, social and economic consequences of the use of legal and illegal psychoactive drugs. Needle and syringe 
exchange, opioid substitution therapy (OST) and other drug dependence treatment, HIV testing, counselling and 
treatment and free condoms are essential components of the comprehensive package of interventions to reduce 
harms associated with injection drug use as defi ned by UNAIDS, UNODC and WHO.1 Harm reduction complements 
approaches that seek to prevent or reduce the overall level of drug consumption but accepts that many people 
who use drugs are unable or unwilling to stop and that many people who use drugs do not need treatment.2 WHO 
also recommends community distribution of naloxone, a medicine that reverses the eff ects of opioid overdose, to 
people likely to witness an overdose.3 
Supply and demand approaches
Supply-side measures aim to restrict the availability of illegal drugs—for example, by eradicating illicit crops, seizing 
illicit drugs, arresting drug traffi  ckers and producers, and providing alternative development options for small 
farmers cultivating illicit drugs. Demand-side measures aim to prevent drug use and to reduce the harmful health 
and social consequences of drug use—for example, through treatment of drug dependence, harm reduction 
interventions and criminalizing possession of drug paraphernalia and drugs for personal use.
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The relationship between drug control policy and human development is complex and multifaceted; both share a 
common objective to reduce drug-related harms. Yet policies aimed at prohibiting and punishing the cultivation, 
sale and use of certain drugs have played a disproportionate role in shaping the international approach to drug 
control and country responses, irrespective of countries’ development goals. Drug control policies have been 
justifi ed by the real and potential harms associated with illicit drug use and markets, such as threats to safety and 
security, public health, crime, decreased productivity, unemployment and poverty.
However, evidence shows that in many countries, drug control policies and related enforcement activities focused 
on reducing supply and demand have had little eff ect in eradicating production or problematic drug use. Various 
UN organizations have also described the harmful collateral consequences of these eff orts: creating a criminal black 
market; fuelling corruption, violence and instability; undermining public health and safety; generating large-scale 
human rights abuses, including abusive and inhumane punishments; and discrimination and marginalization of 
people who use drugs, indigenous peoples, women and youth.4 Evidence shows that in many parts of the world, 
law enforcement responses to drug-related crime have created or exacerbated poverty, impeded sustainable 
development and public health and undermined human rights of the most marginalized people.
The impact of drug control policy on human development 
The complex relationship between illicit drug production, trade and use, on the one hand, and drug control 
policies and human development, on the other, has been recognized for more than a decade. Yet drug control 
agencies and development institutions have tended to operate in isolation from each other. Drug control policies 
and accompanying enforcement practices have emphasized the role of organized crime and corruption in 
impeding human development and focused predominantly on criminal justice solutions. Moreover, development-
sensitive drug control policies have mostly been limited to alternative development programmes that provide 
legal economic opportunities to drug crop cultivators in areas where illicit crops are grown. The root causes that 
sustain the cultivation of illicit crops, their traffi  cking and use, including poverty, food insecurity, lack of land tenure 
or access to markets, have not received suffi  cient attention.
Countering drug-related crime and corruption is important to achieve sustainable development objectives. Weak 
state institutions and a lack of economic opportunities create an environment conducive to illicit activity. In places 
where drugs are produced and traffi  cked, criminal drug organizations foster corruption and undermine the legitimate 
economy. Their actions also undermine democratic governance and citizen security and fuel confl ict. 
Involvement in the drug trade—for example, as sellers or couriers—is also often seen as a viable option for poor 
people, including poor women, unemployed youth, indigenous populations and other marginalized groups for 
whom job opportunities are often limited. Cultivating illicit crops is also often seen as the best livelihoods option 
for poor farmers who live in isolated or confl ict-aff ected areas. 
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Evidence shows that repressive law enforcement approaches and the eradication of illicit crops have had harmful 
impacts on the health and human rights of people living in poverty, including poor farmers and socially and 
economically disadvantaged people living in areas where drugs are produced, traffi  cked or sold. They have 
destroyed the livelihoods of poor farmers and others who depend on cultivating and selling drugs to survive. 
Eradication campaigns have aff ected food security, caused damage to the environment, and forcibly displaced 
populations dependent on illicit crop cultivation as well as those who are not. Problematic drug use, including 
high-risk drug use such as injection and drug dependence is a public health as well as a development issue: it can 
aff ect employment and increase the risk of serious health problems as well as death.
There are eff ective ways to address the harmful health and social consequences of drug use. A substantial body of 
evidence has shown that harm reduction interventions, including distribution of sterile syringes, drug dependence 
treatment and HIV testing and counselling, have proved eff ective in preventing HIV and viral hepatitis and 
preventing and reversing the eff ects of overdose. However, criminal laws, punitive policies and repressive policing 
practices limit and sometimes exclude altogether people who use drugs from access to these services, thus putting 
them at risk of serious disease and in some cases, premature death.
Evidence shows that drug control laws with disproportionately heavy punishments have fuelled mass incarceration, 
often in violation of universally accepted standards of fairness and freedom from torture and ill treatment. Evidence 
also shows that drug control eff orts often have a disproportionate impact on vulnerable groups and marginalized 
communities: peasant farmers, low-level drug off enders, such as those transporting or selling small quantities of 
drugs, and racial and ethnic minorities or indigenous peoples. In many countries, a disproportionate share of those 
incarcerated are poor racial or ethnic minorities. Incarceration, in turn, fuels poverty and social exclusion. 
Those imprisoned on drug-related charges make up a substantial proportion of people in prison worldwide. 
Prison in itself poses a threat to health, with prison populations having worse health outcomes than the general 
population. Harm reduction services are rarely provided, and health services and conditions are overall extremely 
poor. Discrimination, a lack of investment in health and social welfare, and laws criminalizing the use or possession 
of small amounts of drugs for personal use impede access to basic services such as housing, education or health 
care including treatment.
Women often become involved in the drug trade because gender discrimination limits their opportunities for 
education and employment. While they are usually employed at the lowest levels, such as transporting or selling 
small quantities of drugs, they often suff er the same harsh consequences, including severe criminal penalties, as 
those with greater involvement in the drug trade. Women who use drugs often have limited access to eff ective 
health and drug treatment services that take into account their specifi c needs and circumstances. Harm reduction 
and drug treatment programmes, developed to serve an overwhelmingly male clientele, rarely include gender-
specifi c or -sensitive services, and stigma and discrimination by family, service providers and law enforcement 
create additional barriers to treatment and care. 
The way forward: opportunities to address development dimensions 
of drug control
In April 2016, the UN General Assembly will hold a Special Session (UNGASS 2016) on drugs to assess and debate 
the successes and failures of international drug control policies. There is recognition from numerous quarters, 
including several UN Member States, organizations, academia and civil society, of the collateral harms of current 
8  l  ADDRESSING THE DEVELOPMENT DIMENSIONS OF DRUG POLICY
drug policies, and that new approaches are both urgent and necessary. UN Secretary-General Ban Ki-moon has 
urged Member States to use the UNGASS “to conduct a wide-ranging and open debate that considers all options”.5 
The road to 2016 presents UN Member States, UN organizations and all stakeholders with a number of key 
opportunities to engage in a critical discussion about the development dimensions of current drug control policies 
and to consider their diverse impacts on the health and social welfare of individuals, the environment, governance 
and the rule of law. 
The international drug control system recognizes the “health and welfare of mankind” as its overarching concern. 
To succeed in meeting the Sustainable Development Goals (SDGs) as well as drug control objectives, UN 
organizations and Member States should more effectively align drug control efforts with this goal. They should 
commit to supporting the provision of viable and sustainable livelihoods for poor people. They should ensure that 
drug control measures protect human rights and do not impede access to HIV and other health services. As the 
UN programme on development and with the mission of helping countries to simultaneously eradicate poverty 
and signifi cantly reduce inequalities and exclusion, UNDP’s engagement in the UNGASS 2016 discussion could 
contribute to shaping a more comprehensive, eff ective and humane approach to drug policy and positioning 
drug control efforts that reduce drug-related harms and promote human development within the framework of 
the SDGs. The implementation of the SDGs is also another important avenue for advancing development-sensitive 
drug control policies and practices.
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In 2016, the United Nations General Assembly (UNGA) will hold a Special Session on drugs (UNGASS 2016) to 
assess and debate current and future international drug policies. In anticipation of UNGASS 2016, the Commission 
on Narcotic Drugs (CND), the UN organ with primary responsibility for drug control policy, adopted a resolution 
to ensure an adequate, inclusive and eff ective preparatory process for 
UNGASS 2016. This includes extensive consultation allowing relevant 
UN organizations, international and regional organizations, civil society 
and other relevant stakeholders to fully contribute to the process.6 The 
CND has also established a website to facilitate these contributions and 
encourage open and inclusive participation.7
There is increasing recognition among UN Member States, UN organiza-
tions and civil society of the collateral harms of current drug policies, 
and that new approaches are both urgent and necessary. The United 
Nations Offi  ce on Drugs and Crime (UNODC) has stated that the UN drug 
conventions do not require penalization of drug use or drug possession 
for personal use and acknowledged the role of human rights abuses 
against people who use drugs in fuelling HIV.8 UNODC Executive Director 
Yuri Fedotov has encouraged UN Member States to use the upcoming 
UNGASS 2016 and other high-level meetings as opportunities to discuss 
ways to rebalance international drug control policy responses to focus 
more on health and respect for human rights, and address stigma and 
discrimination that limit access to services by people who use drugs.9 
The United Nations System Task Force on Transnational Organized Crime and Drug Traffi  cking was established in 
March 2011 to develop an eff ective, coordinated and comprehensive system-wide approach to crisis situations 
of high levels of drug-related crime and violence, and to provide guidance on how to integrate responses to 
transnational organized crime into UN peacekeeping, peacebuilding, security and development initiatives. The 
Task Force has been given the mandate to facilitate input from all relevant UN agencies into UNGASS 2016. 
Drug control policy aff ects many areas of UNDP’s work. As a member of the Task Force, UNDP is committed to 
providing input on the development dimensions of drug policy that can contribute to a more comprehensive and 
coherent UN system-wide approach to this complex issue. 
Drug policy and human development
The relationship between drug policy and human development is complex and multifaceted. Yet policies aimed 
at prohibiting and punishing the use of certain drugs have shaped the international approach to drug control, 
irrespective of countries’ development goals and policies. For more than 50 years, Member State practice has been 
guided by the three UN drug control treaties—the Single Convention on Narcotic Drugs (1961), as amended by the 
1. INTRODUCTION
“[T]he new framework provides 
a much-needed opportunity to 
integrate the broader United 
Nations agenda, with its inextricably 
linked and mutually interdependent 
peace and security, development, 
and human rights objectives.”
United Nations Secretary-General Ban Ki-moon, 
‘The Road to Dignity by 2030: Ending Poverty, 
Transforming All Lives and Protecting the Planet. 
Synthesis Report of the Secretary-General on 
the Post-2015 Agenda’
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1972 Protocol Amending the Single Convention on Narcotic Drugs; the Convention on Psychotropic Substances 
(1971) and the Convention against Illicit Traffi  c in Narcotic Drugs and Psychotropic Substances (1988)10—and the 
dominant prohibitionist policy directions emanating from associated international bodies. These policies have 
been justifi ed by the real and potential harms associated with drug production, traffi  cking and use, such as threats 
to safety and security, public health, crime, decreased productivity, unemployment and poverty. 
Each year, the UNGA reasserts that “countering the world drug problem” requires an integrated and balanced 
approach that must be carried out in full conformity with the purposes and principles of the UN Charter and, in 
particular, fundamental human rights norms.11 This refl ects the wording it adopted in its 1998 and 2009 Political 
Declarations on Drugs and in commitments made by UN drug control agencies. It also refl ects the drug control 
system’s dual drug control obligation under the conventions: to ensure adequate availability of narcotic drugs and 
psychotropic substances under international control for medical and scientifi c purposes, while at the same time 
preventing the illicit production of these substances or their illicit traffi  cking and use. 
Despite these commitments, the international drug control system seems to have paid less attention to 
consequences for human rights and development than to enforcement and interdiction eff orts. Evidence shows 
that the economic, human and social costs of the implementation of drug policy have been enormous. Current 
drug policies have also diverted public institutional and budgetary resources away from development priorities. 
As an example, globally, the budget for drug-related law enforcement exceeds US$100 billion annually, almost the 
net amount of bilateral Offi  cial Development Assistance (US$134 billion) disbursed by Member countries of the 
Organisation for Economic Co-operation and Development (OECD) in 2013.12 
There are several instances of drug control policies leaving an indelible footprint on sustainable human development. 
Yet drug control policies and coordinating agencies typically have not considered the human development context 
in their responses. Evidence shows that many drug control policies have fuelled the marginalization and exclusion 
of people and communities linked with illicit drug use or illicit drug markets. A growing body of evidence also 
illustrates how the prevailing legal framework and accompanying enforcement practices entrench and exacerbate 
systemic discrimination against people who use drugs, and result in widespread human rights violations. As a 
result, people who use drugs are often among the most marginalized and stigmatized people in society and are 
vulnerable to a wide array of human rights violations. Local communities in drug-producing countries also regularly 
face systematic human rights violations as a result of campaigns to eradicate illicit crops, including environmental 
harms, attacks on indigenous cultures and damage to health from chemical spraying. 
In recent years, there has been increased attention to the multidimensional relationship between drug control and 
development outcomes.13 UNODC has recognized the “vicious cycle” of drug production, drug traffi  cking, poverty 
and instability, as well as the harmful consequences of drug control policies on the health and human rights of 
people who use drugs and those who live in communities where drugs are cultivated. UNODC has also highlighted 
the “right to development” in its ‘World Drug Report’ and together with UN Member States called on governments 
to address problem drug use as a health and not a criminal issue.14 UN Secretary-General Ban Ki-moon has identifi ed 
illicit drugs and crime as a “severe impediment” to achieving sustainable development, as well as to securing human 
rights, justice, security and equality for all. He has urged Member States to “ensure that the sustainable development 
pillar [of the post-2015 development agenda] contains elements combating illicit drugs and crime, while also 
ensuring that drug control and anti-crime strategies are sensitive to the needs of development”.15 
UNDP, on behalf of the Joint United Nations Programme on HIV/AIDS (UNAIDS), convened an independent Global 
Commission on HIV and the Law. The Commission, comprising 14 internationally recognized leaders in HIV, public 
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health, law and development, examined the key legal and human rights issues confronting the AIDS response, 
including the criminalization of behaviours and practices such as drug use. Twenty-four internationally recognized 
leaders in HIV, public health, law, development, human rights and drug policy, including the former presidents of 
Brazil, Chile, Colombia, Mexico, Nigeria, Poland, Portugal and Switzerland, convened the Global Commission on 
Drug Policy. Both commissions raised concerns about the health and human rights consequences of drug control 
policies, and called for the consideration of viable alternatives to the current prohibitionist approach.16
The global community is currently discussing the SDGs Agenda, intended to guide global development eff orts for the 
next 15 years. Many drug policy experts have pointed out potential contradictions between the proposed SDGs and 
current drug policies stemming from the three international drug control conventions. For example, the SDGs aim to 
end poverty and hunger, protect the environment and promote sustainable livelihoods as well as health and well-
being for all. However, current drug policies and their collateral consequences threaten these goals. They have fuelled 
and escalated violence and diverted limited funds and political attention away from public health and focused them 
disproportionately on law enforcement. They have also impeded access to lifesaving harm reduction interventions and 
essential medicines to treat pain and drug dependence. Drug production and traffi  cking, and related law enforcement 
activities, damage the environment by polluting water, contaminating soil and harming protected forests. At the same 
time, the international community, led by international and domestic drug control agencies and experts, is engaged 
in a global debate in the lead-up to UNGASS 2016.
The SDGs and UNGASS both provide important opportunities for defi ning the new global agenda for development 
and for evaluating the international drug control system. UNDP’s mission is to help countries eradicate poverty 
while also reducing inequalities and exclusion. Its active involvement in the UNGASS 2016 discussion could have 
an important infl uence on shaping drug policies that eff ectively incorporate and support these goals. Guided 
by its ‘Strategic Plan 2014–2017’, which states “the challenge is to rethink development”, UNDP could play an 
important role in several ways: for example, fi rst, by highlighting the linkages between drug policy, public health 
and sustainable human development; and, second, by bringing to the discussion UNDP’s knowledge, empirical 
experience and capacity on human development issues, thereby helping to frame the development dimensions 
of drug control policies and, in turn, providing an evidence base for development-sensitive drug control policy. 
The purpose of this paper is to:
  articulate a narrative of how current drug policy aff ects human development, including UNDP’s mandate 
and activities;
  highlight opportunities for UNDP to address the development dimensions of drug policy; and
  propose entry points for UNDP’s engagement on development-sensitive drug policy in the UN system, 
including the post-2015 development agenda, and preparations for UNGASS 2016.
The remainder of this paper is divided into three sections:
  An overview of how current drug policies intersect with various human development outcomes of 
relevance to UNDP
  Proposals for how UNDP might best articulate the importance of human development in international 
norm-setting forums and domestic programme delivery on drug control and policy
  A conclusion, including a review of key opportunities for UNDP to address the development dimensions 
of drug control policy
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The international drug control system, comprising the three drug control 
treaties,17 recognizes the “health and welfare of mankind” as its overarching 
concern.18 It establishes a “dual drug control obligation: to ensure adequate 
availability of narcotic drugs, including opiates, for medical and scientifi c 
purposes, while at the same time preventing illicit production of, traffi  cking 
in and use of such drugs”. 19 There is growing evidence, however, that 
current drug control policies have caused considerable harm to health, 
social and economic development, and to peace, security and stability. 
Meanwhile, a growing body of evidence shows that in many countries 
policies focused on supply and demand reduction and related enforcement activities have had little meaningful 
eff ect in eradicating production or on problematic drug use.20
UNODC has identifi ed a number of negative “unintended consequences”21 of current international drug control 
policies:
  the creation of a lucrative and violent criminal black market for drugs of macroeconomic proportions;
  policy displacement from health to law enforcement, drawing limited funds and political attention away 
from public health and focusing them disproportionately on public security and law enforcement; 
  geographic displacement, otherwise known as the ‘balloon eff ect’:22 displacing production and transit, 
and with it, crime, violence and destabilization, to new geographic areas to meet demand;
  substance displacement: switching to a drug with similar eff ects but less stringent controls, creating new 
patterns of drug use and markets; and
  the criminalization and marginalization of people who use drugs, often amplifi ed through the use of the 
criminal justice system to address drug use and minor possession.23
As discussed below, increasing evidence demonstrates additional harmful eff ects of drug control policies and 
related law enforcement practices on development outcomes, particularly poverty and sustainable livelihoods; 
governance and the rule of law; human rights; gender equality; the environment; and on indigenous peoples and 
traditional and religious practices.
2. THE IMPACT OF DRUG CONTROL POLICY 
 ON HUMAN DEVELOPMENT 
“We must have the courage 
to change policies that no longer 
fi t reality.” 
Olusegun Obasanjo, Chair, 
West Africa Commission on Drugs, 2014 
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2.1 Poverty and sustainable livelihoods
The cultivation of illicit drug crops is strongly linked to poverty, 
and driven by socio-economic, security-related, agricultural and 
environmental factors. As the European Union has observed:
“[I]llicit drug crop cultivation is concentrated in areas where 
confl ict, insecurity and vulnerability prevail. Poor health, 
illiteracy and limited social and physical infrastructure refl ect 
the low level of human development experienced by the 
population in these areas.”25
Many people living in conditions of poverty and insecurity may 
often consider the cultivation of illicit crops their best livelihood 
option. Coca, opium poppy and cannabis are non-perishable, 
high-value commodities that can be grown in marginal terrain, in 
poor soil, with limited or no irrigation, and can provide income for 
those who are land, food and cash-poor.26 But illicit drug economies 
do not address the structural drivers of illicit crop cultivation or 
promote improvements in access to food, housing, education and land distribution. In addition, cultivators may 
face violence at the hands of state eradication campaigns and criminal, insurgent and non-state actors involved in 
production and traffi  cking. 
Poppy fi elds in Afghanistan, United Nations
“Let us not forget that behind 
the policies, we have hundreds of 
thousands of farmers aff ected 
by poverty, food insecurity, lack of 
land, instability who [as] a result 
engage in illicit drug cultivation. It is 
our common responsibility to continue 
addressing the livelihood of these 
people...”
Yuri Fedotov, Executive Director, UNODC24
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The vast majority of poor farmers in drug-producing countries grow illicit drugs because of poverty, mainly to meet 
basic needs. The enforcement of opium, coca, cannabis and khat bans as well as crop eradication interventions have 
eliminated the principal source of income of thousands of families, driving them further into poverty.27 Evidence 
suggests that the destruction of coca plants and traditional crops has aff ected food security, contaminated water 
supplies and degraded land, thus displacing populations dependent on coca as well as those who are not.28 
People at lower levels of the drug trade, such as street-level dealers, peasant farmers, small-scale traffi  ckers and 
others involved throughout the chain in production, transportation and distribution are sometimes paid for their 
work with drugs instead of money.29 In some cases, particularly in areas in confl ict or under the control of non-state 
actors, drugs replace money for commercial exchanges, and in some cases are used for political infl uence and to 
buy votes.30 In any event, receipt of such payments and their ongoing use in place of cash may make them drug 
traffi  ckers in the eyes of the law, thus increasing their risk of criminal punishment.
Law enforcement operations, including crop eradication campaigns, as well as drug-related armed confl ict fuel 
displacement, with disproportionate impacts on less developed communities, including indigenous communities 
and ethnic minorities.31 The appropriation and protection of land for the cultivation of illicit crops and access to 
traffi  cking routes, confl icts over the control of production and distribution and forced eradication of crops have 
been identifi ed as key factors fuelling internal displacement.32 Displacement exacerbates the poverty of poor 
farmers, leading them to continue or begin cultivation of illicit drug crops as a source of livelihood.33
Conditions of scarcity, displacement, state neglect, economic and geographic isolation and livelihoods insecurity, 
including in situations of confl ict, increase the vulnerability of peasants and poor farmers to engaging in drug 
crop production.34 Evidence shows that political instability, weak governance systems, poverty, loss of livelihoods, 
inequality and social exclusion, as well as conditions of insecurity and the proliferation of small arms in post-
confl ict environments, also exacerbate the vulnerability of countries, territories and communities used as transit 
routes and for traffi  cking activities.35 
Over the past two decades, the international community has begun to recognize the development dimensions of 
drug crop cultivation and, to a far lesser extent, drug production and traffi  cking.36 UNODC and the World Bank, for 
example, have identifi ed multidimensional poverty, food insecurity, lack of land tenure, and insecurity in the face 
of armed confl ict as key drivers of illicit crop production.37 Along with development experts, they have, therefore, 
emphasized the importance of addressing poverty, together with other root causes of illicit crop production, in 
order for illicit cultivation to be reduced sustainably.38 As the European Union has observed:
“[N]o single project or program can address the multiple factors that drive illicit drug production. ...Evidence 
points to the fact that it is a combination of improved governance, security and economic growth that will 
deliver the development impact required to improve the life and livelihood of primary stakeholders and reduce 
illicit drug [crop] cultivation. ...[D]evelopment assistance in illicit crop producing areas should be undertaken in 
full compliance with the overall aims of human rights protection, poverty alleviation, confl ict prevention and 
resolution, peace building and human security.”39
Alternative development programmes that provide legal options to drug cultivation have been promoted as a 
way to wean farmers off  drug crop production and onto legal crops or other non-agricultural activities. Alternative 
development policies have been aligned with drug control, public security and trade priorities rather than public 
health and development ones. The success of these alternative development programmes has been measured 
as a reduction in drug crop cultivation at the local or national level, without always taking into account human 
development indicators or the ‘balloon eff ect’ on other regions.40 Several factors have curtailed their eff ectiveness 
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and potential impacts on development, as well as increased vulnerability of target communities. These include the 
failure to ensure that viable, sustainable livelihoods are established and alternative sources of income are in place 
prior to signifi cant drug crop productions, local ownership or meaningful participation of farmers, as well as poor 
design, fragmented implementation and poor funding.41 
The European Union, the Organization of American States (OAS) and UNODC have all taken the position that 
eff orts to address illicit drug cultivation should be mainstreamed into national poverty reduction strategies, confl ict 
prevention eff orts and development programmes.42 To this end, development experts have also pointed out that 
successful alternative development depends on many factors including long-term investments by governments 
and international donors; integration of sustainable livelihood strategies in local, regional and national development 
plans; coordination of drug control and development experts and agencies; existence of sound monitoring and 
evaluation mechanisms; local ownership; development of markets and infrastructure for crops or products that 
replace drug crops; and the meaningful involvement of farmers as citizens with rights and partners in development.43
2.2 Impact on public health
 
A UNODC report published in 2014 estimates that approximately 243 million people, or 5.2 percent of the world’s 
population, used illicit drugs in the past year. Of these, about 10 percent are classifi ed as ‘problem drug users’—
people who engage in high-risk consumption of drugs, such as injection drug use, and people who are drug-
dependent.44 Worldwide, an estimated 12.7 million people inject 
drugs.45 
Some of the most severe drug-related harms are associated with 
injection drug use. Outside sub-Saharan Africa, up to 30 percent of 
all new HIV infections occur among people who inject drugs. Unsafe 
injecting practices put people who inject drugs at high risk of blood-
borne infections such as HIV and viral hepatitis, in particular hepatitis 
B and hepatitis C.46 People who inject drugs are also at great risk of 
tuberculosis, which is a leading cause of death among people who use 
drugs, particularly those with HIV.47 Worldwide, an estimated 1.7 million, 
or 13.1 percent of people who inject drugs, are living with HIV.48 Similar 
high HIV prevalence rates have been reported among non-injection 
drug users, such as people who consume drugs by snorting, smoking, 
inhaling, ingesting or rectal insertion.49 
Worldwide, drug overdose is the main cause of drug-related deaths, 
and most overdoses involve opioids, including heroin.50 Polydrug use, 
reduced tolerance due to abstinence—for example, post-incarceration 
or detoxifi cation treatment—and lack of access to opioid substitution 
treatment (OST) are some key risk factors that lead to overdose.51 Opioid 
overdose is preventable and treatable, if treatment with naloxone is 
available.52 OST—for example, with methadone or buprenorphine—
reduces the risk of injection and thus overdose by almost 90 percent53 
but is scarce or unavailable in most countries.54 
“A new and improved global drug 
control regime is needed that better 
protects the health and safety 
of individuals and communities 
around the world. Harsh measures 
grounded in repressive ideologies 
must be replaced by more humane 
and eff ective policies shaped by 
scientifi c evidence, public health 
principles and human rights 
standards. This is the only way to 
simultaneously reduce drug-related 
death, disease and suff ering and the 
violence, crime, corruption and illicit 
markets associated with ineff ective 
prohibitionist policies.”
The Global Commission on Drug Policy, ‘Pathways to 
Drug Policies that Work’ (2014)
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As UNODC has noted, repressive drug control policies encourage the shift to new drugs with similar eff ects but 
subject to less control. ‘Substance displacement’ to new drugs and patterns of use exposes people who use drugs 
to serious, sometimes fatal harms, in part because of the speed with which they appear, and particularly with 
respect to new psychoactive substances, the lack of information about their eff ects and harms and the lack of 
eff ective treatment such as OST to address drug dependence and overdose. The European Monitoring Centre for 
Drugs and Drug Addiction has attributed the increase in serious harms from drug use, including deaths and non-
fatal intoxications, to the growth in the market for new psychoactive substances, 101 of which were identifi ed in 
2014 alone.55 
People imprisoned on drug-related charges make up a substantial proportion of prison populations worldwide. 
Prisoners, in turn, have much higher rates of drug use, especially injection drug use, than the general population.56 
Despite recommendations by UNODC, WHO and UNAIDS that harm reduction services should be provided in 
prisons, they rarely are. As a result, prisoners often share syringes, thus increasing their risk of contracting HIV, viral 
hepatitis and other communicable diseases.57
HIV PREVALENCE AMONG PEOPLE WHO INJECT DRUGS
Source: UNAIDS, 2014, ‘The Gap Report’
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Needle exchange programme at the Humanitarian Action Fund’s mobile clinic in St. Petersburg, Russia, Open Society Foundations
A substantial body of evidence shows the eff ectiveness of harm reduction interventions in preventing HIV and 
viral hepatitis, and preventing and reversing overdose. In light of this evidence, UNODC, WHO and UNAIDS all 
recommend that a comprehensive package of harm reduction services should be integrated into national AIDS 
programmes, both as an HIV prevention measure and to support adherence to antiretroviral therapy and medical 
follow-up for people who use drugs.58
Harm reduction has gained increasing acceptance at the national level in recent years, with a growing number of 
countries including harm reduction in their national policies and establishing harm reduction services. Nonetheless, 
as UNODC and Harm Reduction International have documented, coverage is far short of what is needed.59 For 
example, coverage is limited in many sub-Saharan African countries with new and emerging patterns of injection 
drug use, and non-existent in many countries in the Middle East and North Africa region, one of two regions in 
the world where HIV infection rates continue to increase, and where rates of injection-related HIV transmissions 
are high. The Russian Federation, which has the largest HIV epidemic outside sub-Saharan Africa, largely related to 
injection drug use, bans OST.60
Evidence shows that harm reduction interventions not only save lives, they save money. Public health cost-
eff ectiveness experts focusing on HIV and drug use have, therefore, consistently and repeatedly called on countries 
with signifi cant HIV epidemics among people who use drugs to invest immediately in harm reduction. They have 
also advised that failure to do so will bring enormous and avoidable human and fi nancial costs.61 
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Source: Harm Reduction International, 2015, ‘The Global State of Harm Reduction 2014’
GLOBAL HARM REDUCTION RESPONSE: ACCESS TO OPIOID SUBSTITUTION THERAPY
In 2014, WHO’s technical guidance on HIV prevention, diagnosis, treatment and care for key populations 
recommended decriminalizing drug use because that measure would serve as a “critical enabler” to create 
conditions conducive to providing health and social services, and preventing HIV, among people who use drugs.62
However, evidence shows that criminal laws and related enforcement policies and practice have impeded access 
to these lifesaving health services in many countries. These include laws and policies that criminalize possession 
or distribution of sterile syringes and other drug paraphernalia, OST, and peer outreach to people who use drugs; 
government registration of people who use drugs on registries accessible to police; and abusive policing practices. 
This has put people who use drugs at increased risk of HIV, viral hepatitis, and other communicable diseases, as well 
as premature death by overdose.63 
Concerns about the harmful eff ects of a punitive criminal justice approach on the health and human rights of 
people who use drugs have prompted a number of governments to reject the criminalization of possession of 
small quantities of drugs for personal use, either in law or in practice.64 Portugal and the Czech Republic have 
decriminalized possession of small quantities of all drugs for personal use, while in The Netherlands and Germany, 
for example, possession for personal use is illegal, but guidelines are established for police and prosecutors to 
avoid imposing punishment.65 Many Latin American countries, including Colombia, Mexico and Argentina, have 
removed criminal sanctions or decriminalized small-scale possession for personal use, either by court decree 
OST available in the community
OST available in the community and prison
OST not available
OST available in the community
OST available in the community and prison
OST not available
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or through legislative action.66 While it is diffi  cult to make generalized conclusions across a wide range of such 
decriminalization policy models, longitudinal and comparative analyses suggest that there is no clear link between 
more punitive enforcement and lower levels of drug use, and that moves towards decriminalization are not 
associated with increased use.67 In Portugal, for example, since 2001, when the law decriminalizing the possession 
and use of illicit drugs in small enough amounts to suggest personal use came into eff ect, there has been a small 
rise in drug use, which is comparable to neighbouring countries, and a rapid decline in HIV incidence linked to 
injection, as well as decreases in school-age drug use and injecting drug use by school-age children and a fall in 
lifetime heroin use in 16–18-year-olds.68
The drug conventions require governments to take steps to reduce supply and demand for controlled drugs. These 
eff orts should be balanced with States’ obligations to ensure an adequate supply of narcotic and psychotropic 
drugs for medical and scientifi c purposes and consistent with their human rights obligations. The obligation to 
provide access to essential medicines is a core component of the right to health.69
Several drugs subject to control under the international drug control conventions are also on the WHO’s Model 
List of Essential Medicines, including morphine for pain treatment, and methadone and buprenorphine for OST.70 
WHO has recognized that strong opioids, such as morphine, are essential for the relief of moderate to severe pain, 
and that providing methadone or buprenorphine for the treatment of opiate drug dependence is essential to 
Source:  Global Commission on HIV and the Law, 2012, ‘HIV and the Law: Risks, Rights & Health’
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meet minimal standards of health care provision.71 Despite this, worldwide, only a fraction of people who inject 
drugs have access to OST.72 Three quarters of the world’s population has no or insuffi  cient access to treatment 
for moderate to severe pain, and each year tens of millions of people suff er untreated moderate to severe pain. 
Unnecessarily restrictive drug control regulations and practices are a signifi cant barrier to access to eff ective pain 
treatment, as recognized by the INCB and WHO.73
2.3 Impact on the formal economy 
Current drug control eff orts have fuelled the creation of a criminal black 
market for illicit drugs, which has an estimated turnover of more than 
US$332 billion annually. 75 Illicit drug markets are substantial due to their 
high value, driven by a sustained demand. Illegal drugs are a potential 
source of wealth and often become profi table industries for criminal 
networks and livelihoods. The illicit drug market can also attract those who 
may not have the requisite education or opportunities to join the formal 
economy, such as small farmers and unskilled labourers. 
While the illegal drug market may generate economic growth, economic 
inclusion and employment, thus improving the lives of some who are 
involved, it also poses a threat to long-term development objectives and 
outcomes. Illegal businesses, often associated with money laundering 
schemes, aff ect formal economies in many ways, including the distortion 
of markets, exacerbating income inequality, undermining the rule of law 
and fuelling corruption. 
Drug markets can also undermine economic development by eroding 
social cohesion, degrading quality of life and forcing skilled workers to 
leave, while the direct impacts of victimization, as well as fear of crime, may 
impede the development of those who remain.76 Violence and insecurity 
associated with illicit drug markets also drive up the costs of legitimate trade and commercial activities, and in turn 
discourage investment in aff ected regions.77 Sectors such as tourism can be especially sensitive to these dynamics.78
Illegal producers and traffi  ckers often need to create front companies to launder and conceal illicit drug money, 
which creates unfair advantages over legitimate enterprises. Front companies do not have to turn profi ts for their 
owners, and may crowd legitimate businesses out of the market by selling goods at below market rates, in some 
cases leaving entire sectors in the control of illegal enterprises, as well as deterring local and foreign investment 
activities.79 
UNODC and others have recognized that drug control eff orts have had signifi cant macroeconomic and policy 
eff ects, redirecting foreign and domestic investment in social and economic projects to funding for military and 
law enforcement eff orts to address drug traffi  cking and production.80 The existence of a large illicit sector in the 
economy can also distort economic data and, in turn, macroeconomic and structural analysis and policymaking.81 
“Global drug control eff orts have 
had a dramatic unintended 
consequence: a criminal black 
market of staggering proportions. 
Organized crime is a threat to 
security. Criminal organizations 
have the power to destabilize 
society and governments. The illicit 
drug business is worth billions of 
dollars a year, part of which is used 
to corrupt government offi  cials and 
to poison economies.”74 
Antonio Maria Costa, 
UNODC Executive Director, 2002–2010
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The OECD encourages its Member countries to include the ‘non-observed economy’, which includes illegal 
activities, in their respective estimates of Gross Domestic Product (GDP), and several countries, such as Austria, 
Canada, Czech Republic, Netherlands, Norway and Poland, have done so.82 The production and distribution of 
illegal drugs is a major activity in some countries of Latin America, West Africa and Asia. The value added due to 
these activities could infl ate GDP measures signifi cantly and distort Human Development Index metrics and other 
indicators. UNDP’s discussion of drug control policy presents a timely opportunity to consider the merits of an 
economic growth metric that includes income linked to the illicit drug trade.
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Illegal drug economies attract human capacity whose entrepreneurial spirit might otherwise be used to drive lawful 
productive activity and increase economic competitiveness. This loss is greater in areas or countries where human 
resources are harder to come by, and it represents more serious opportunity costs for low-growth economies with 
limited production capabilities.
What the illegal economy gains from prohibition, in terms of freedom from taxation, the legal economy loses: the 
tax base becomes smaller at the same time that expenditures on police, courts and prisons are on the increase.83 As 
UNODC has observed, resources are not fi nite: funds directed toward public security and law enforcement reduce 
the availability of resources for other activities or services critical for development, such as education, infrastructure, 
environmental conservation and social protection. 
The economic costs of drug law enforcement, measured in terms of incarceration of drug off enders, are also 
signifi cant. For example, the US Offi  ce of National Drug Control Policy estimated lost productivity of the population 
of people incarcerated for drug off ences in 2002, about 663,000 people, to be $39 billion.84
2.4 Impact on governance, confl ict and the rule of law 
Illicit drug markets undermine the ability of the State to promote development, by destroying trust between 
citizens and the State, and undermining democracy and confi dence in the criminal justice system.85 Organized 
illicit activity is often able to co-opt local and national institutions, destabilize the government and undermine 
inclusive political processes, adversely aff ect delivery of justice and security services and foster impunity for other 
kinds of criminal activity. Evidence shows that profi ts from illegal drug trade support corruption, fund insurgent, 
paramilitary and terrorist groups, and, in turn, fuel regional instability in parts of Latin America, the Caribbean, Asia 
and Africa.86 
Evidence from around the world shows that weak state institutions, an absence of basic infrastructure and a lack 
of economic opportunities create enabling conditions for the drug trade to fl ourish.87 Criminal drug organizations 
typically concentrate operations in regions where such conditions exist, and secure and expand their business by 
paying off  private individuals and police, judiciary and political offi  cials.88 
As UNODC has observed:
“The magnitude of funds under criminal control poses special threats to governments, particularly in developing countries, where 
the domestic security markets and capital markets are far too small to absorb such funds without quickly becoming dependent on 
them. It is diffi  cult to have a functioning democratic system when drug cartels have the means to buy protection, political support 
or votes at every level of government and society. In systems where a member of the legislature or judiciary, earning only a modest 
income, can easily gain the equivalent of some months’ salary from a traffi  cker by making one ‘favourable’ decision, the dangers of 
corruption are obvious.”89
Organized crime has the potential to usurp the rule of law where the State is weak. Its fi nancial and human resources 
can be used to obtain popular support, political and economic infl uence or protection from law enforcement and 
justice, to the point of endangering the integrity of state institutions. This, in turn, erodes democratic governance. 
The more the State is permeated with the infl uence of the drug trade, the more diffi  cult transparency and 
accountability becomes. At the same time, the more public institutions and procedures are weakened, the more 
they are susceptible to being permeated by the illegal drug economy, in some contexts on a large scale.90 
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Moreover, the illicit drug trade, because of the short-term benefi ts associated with it, can gain legitimacy in some 
communities, with traffi  ckers developing social networks to protect their wealth.91 The existence of a profi table illicit 
market can also undermine citizen security. Evidence shows that the illicit drug trade has fuelled and exacerbated 
violence, confl ict, crime and corruption, and contributed to the instability of governments throughout parts of 
Latin America, the Caribbean, Asia and Africa.92 The illicit drug trade can also result in income inequality which may 
then disturb power structures within communities, erode traditional social structures and encourage more people 
to enter the illicit drug industry.93
Criminal drug producers and traffi  ckers thrive in fragile, confl ict-aff ected and underdeveloped regions. Countries 
with weak democratic institutions that lack transparency “are particularly at risk, and the consequences may well 
be devastating in terms of the extent of public corruption, penetration of state institutions, infl uence peddling, and 
manipulation of the justice system”.94 In recent decades, as international drug traffi  ckers have used West African 
countries as a transit hub for shipping cocaine and other drugs into Europe. Drugs worth billions of dollars have 
passed through the region, and drug traffi  ckers have used some of the profi ts to fuel corruption in the region.95 
Evidence shows that drug-traffi  cking and money-laundering networks have fi nanced political parties and 
campaigns in a number of countries, securing infl uence at the domestic and international level.96
UNDP has recognized that in Latin America, for example, policies focusing predominantly on repression, increased 
penalties and the use of force have increased lethal violence and police abuse, fuelled belligerent responses from 
criminal organizations and provoked their fracture and geographic dispersion. Successful interdiction eff orts, 
Border force offi  cers in Ghana searching a consignment of children’s lollipops containing cocaine en route to the UK, UK Home Offi  ce
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the arrest or extradition of drug cartel leaders and the destruction of drug cartels have led to increased levels of 
violence, as the remaining players compete to control market share.97 
As UNODC has also observed, drug control eff orts have not eliminated drug supply. Instead, enforcement pressure 
on one production area or transit route displaces production or traffi  cking routes, and related crime, violence and 
destabilization, to new geographic areas and communities. Transit countries often also experience an increase in 
drug consumption, which in turn can lead to an increased burden on the health system.98 This ‘balloon eff ect’ has 
shifted coca production between countries in Latin America, displaced opium production from China to Thailand and 
Myanmar, and moved drug transit routes back and forth between Mexico and the Caribbean and into West Africa.99 
In fi ghting transnational organized crime, some authorities have turned to alternative methods of procuring 
security, and implemented more focused, community-based deterrence strategies and selective targeting 
approaches that seek to minimize the most pernicious behaviour of criminal groups while tolerating less harmful 
behaviours. Such an approach also enables overwhelmed law enforcement institutions to overcome problems of 
under-resourcing.100 UNDP has cautioned that in extreme cases, community-based deterrence has devolved into 
lynching or ‘social cleansing’, in some cases with the participation of state actors.101 
The excessive use of criminal justice mechanisms, the disproportionality of incarceration penalties for drug-related 
off ences, and the enforcement of mandatory sentencing laws have contributed to overloading the judicial and 
prison systems, undermining their capacity to deliver justice and support rehabilitation.102 The lack of alternatives 
to incarceration and re-entry mechanisms and the excessive use of pre-trial detention have, in many instances, 
contributed to serious prison overcrowding, facilitating human rights abuses, as well as connections to organized 
crime networks within prison.103
2.5 Human rights implications of drug policy
In many countries around the world, drug control eff orts result in human 
rights abuses: torture and ill treatment by police, mass incarceration, 
extrajudicial killings, arbitrary detention, and denial of essential medicines 
and basic health services. Local communities in drug-producing countries 
regularly face violations of their human rights as a result of campaigns to 
eradicate illicit crops, including environmental damage, an undermining 
of indigenous cultures, and displacement and damage to health from 
chemical spraying. Communities also often face serious human rights 
abuses by large-scale drug traffi  cking organizations, including massacres, 
killings, forced displacement, sexual and physical violence and extortion.105
Evidence shows that drug control laws with disproportionately heavy 
punishments have fuelled mass incarceration, often in violation of universally 
accepted standards of fairness and freedom from torture and ill treatment.106 
Sentences for small-time drug dealing are sometimes lengthier than sentences 
for serious acts of violence such as murder, rape or armed robbery,107 and have 
strongly contributed to the deterioration of living conditions in many prisons 
and to the extended use of longer pre-trial detention periods without any 
resolution of the prisoner’s status. Some children of women sentenced to long 
prison terms for drug-related crimes grow up inside prisons, many of them 
not fi t to maintain the basic conditions to live with di gnity.108
“Placing human rights at the centre 
of drug control, crime prevention 
and criminal justice provides an 
organizing set of principles that 
dissolves boundaries between 
the fi elds and promotes a single 
coherent response. Eff ective drug 
control cannot exist without fair 
criminal justice and successful crime 
prevention. ...Such an approach 
represents more than ‘added value’; 
it is a legal obligation.” 104 
Antonio Maria Costa, 
UNODC Executive Director, 2002–2010
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Table 1.  Sample of countries with mandatory death penalty for drug off ences*
Country Number of
death sentences/
executions in 2011
Number of
death sentences/
executions for drug-
related off ences in 2011
Percentage of death 
sentences/
executions for drug 
off ences
Islamic Republic of Iran 676 540 80%
Kuwait 17 3 18%
Malaysia 108 83 77%
Singapore 4 2 50%
United Arab Emirates 31 7 23%
Vietnam 69 27 39%
Yemen 29 10 34%
Note: * Data compiled from P. Gallahue, R. Gunawan, F. Rahman, E.M. Karim, U.D. Najam and R. Felton, ‘The death penalty for drug off ences. 
Global overview 2012: Tipping the scales for abolition’, International Harm Reduction Association, London, 2012. 
Evidence also shows that drug control eff orts often have a disproportionate impact on vulnerable groups and 
marginalized communities: peasant farmers, low-level drug off enders, and racial and ethnic minorities or indigenous 
peoples.109 In many countries, a disproportionate share of those incarcerated are poor racial or ethnic minorities.110
More than 235,000 people are arbitrarily detained, often without their consent and or any form of due process, 
in over 1000 compulsory drug detention centres in East and Southeast Asia, under the guise of ‘treatment’ or 
‘rehabilitation’.111 UN human rights agencies and human rights experts have called for the closure of these centres, 
citing a wide range of human rights violations such as forced labour, including child labour; judicial, State-sanctioned 
corporal punishment and other forms of physical, psychological and sexual violence; poor conditions of detention; 
arbitrary detention; and denial of medical care.112 In 2012, for example, UNDP and 11 other UN organizations issued 
a joint statement calling for the immediate closure of compulsory drug detention centres, emphasizing the health 
and human rights risks to detainees.113
UN guidance recognizes that drug dependence is a chronic, relapsing condition and that several episodes or types 
of treatment may be required to overcome it.114 Yet in some countries, ‘drug courts’ have obliged many people with 
drug dependence to follow abstinence-based treatment and subjected them to additional penal measures if they 
fail ‘treatment’.115
The death penalty for drug-related crimes is a violation of international law. Yet 33 countries and territories retain 
this penalty, and up to 1000 people are executed annually for drug off ences.116 Drug enforcement eff orts have led 
to extrajudicial killings by police and military.117  Targeted killings of drug traffi  ckers have also been justifi ed as a 
military intervention, in violation of international humanitarian and human rights law.118
These and other human rights violations which occur within the context of drug control eff orts violate numerous 
fundamental human rights, including: the right to life; the right to be free from torture, cruel, inhuman and degrading 
treatment; the right to health; the right to non-discrimination; and the right to liberty and security of person. In 
particular, laws and policies that contribute to unnecessary morbidity and preventable mortality constitute specifi c 
breaches of the obligation to respect the right to health119 and represent a failure on the part of States to meet 
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their obligations under the right to health to take all steps necessary for the “prevention, treatment and control of 
epidemic diseases” and the “creation of conditions which would assure to all medical service and medical attention 
in the event of sickness”.120 International human rights treaties place obligations on UN Member States to adopt 
‘positive measures’ to increase life expectancy and eliminate epidemics121—for example, by providing access to 
HIV prevention, care and treatment services. However, criminal drug laws and related enforcement practices often 
deny access to lifesaving health services in many countries.122
2.6 Gender dimensions
Women who use drugs and women whose male sex partners use drugs face multiple issues that enhance their 
vulnerability to HIV, sexually transmitted infections and violence. Research also indicates that women who use 
drugs face high rates of violence by intimate partners as well as law enforcement offi  cers.123 Notwithstanding 
the global commitment to universal access to harm reduction and related services, women who use drugs often 
have limited access to eff ective health and drug treatment services that take into account their specifi c needs and 
circumstances. Social and structural factors creating barriers to treatment and care include a lack of gender-specifi c 
services, and stigma and discrimination by family, service providers and law enforcement.124
In many countries, women with a history of drug use are considered unfi t to parent. Pregnant women who use drugs 
may be pressured to have abortions or to give up their newborn infants, and mothers with a history of drug use 
often have problems maintaining custody of their children.125 In some countries, pregnant women who use drugs 
face civil or criminal detention for extended periods of time—in some cases, for the length of the pregnancy.126
Women are also involved in the cultivation, sale and traffi  cking of drugs, usually at the lowest levels, such as 
transporting or selling small quantities of drugs. Yet they often suff er the same harsh consequences as those with 
greater involvement in the drug trade. In many countries in Latin America, for example, drug law enforcement 
results in disproportionate penalties by subjecting ‘drug mules’ to the same severe penalties as large-scale drug 
traffi  ckers.127 Although men and women act as ‘drug mules’, a higher percentage of women are detained.128 
A substantial proportion of women in prison are incarcerated for low-level, non-violent drug off ences—between 
40 and 70 percent in some countries in the Americas, Europe and Central Asia.129 Many of them are young, illiterate 
or with little schooling, single mothers, and responsible for the care of their children or other family members. 
While more men are incarcerated for drug off ences, the consequences of criminal punishment fall diff erently on 
women, and often have a greater impact on their children and their families. Yet women’s caring responsibilities 
are not taken into account at sentencing, nor recognized or met in prison. Prison sentences for women may result 
in the incarceration of their infants and young children, who stay with them for all or part of their sentence and/or 
the abandonment of the incarcerated women by their families outside.130 Children left behind may then engage 
in criminal activity or problem drug use as they struggle to cope with living on the streets, in institutions, in foster 
care or with relatives.131 
Indigenous peoples in developed as well as underdeveloped countries consistently lag behind the non-indigenous 
population in most indicators of well-being. They have higher rates of poverty and illiteracy, with the rates 
often highest among indigenous women.132 Their poverty and low levels of education, coupled with the lack of 
interpreters in law enforcement and in the judicial system, make it extremely diffi  cult for them to understand the 
processes against them, and puts them at risk of signing incriminating documents, including confessions that they 
do not understand.133 
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This gender-diff erentiated experience illustrates that long-term incarceration not only creates an economic burden 
but also suggests serious, far-reaching consequences not only for individual off enders and their families but also 
for society as a whole. However, the gender dimensions of current drug policies and legislation have yet to be 
comprehensively assessed.134
2.7 Impact of drug control policies on the environment 
The 1988 Convention against Illicit Traffi  c in Narcotic Drugs requires State Parties to “take appropriate measures to 
prevent illicit cultivation of and to eradicate plants containing narcotic or psychotropic substances”. These measures 
must “respect fundamental human rights and shall take due account of traditional licit uses, where there is historic 
evidence of such use, as well as protection of the environment” (article 14(2)). In practice, however, eradication 
campaigns have had devastating consequences for the environment.135
Drug cultivation, production and related traffi  cking and enforcement activities can also cause serious harm to the 
environment, including: deforestation; soil erosion and degradation; loss of endemic species; contamination of 
soil, groundwater and waterways; and the release of numerous gases that fuel climate change, such as methane, 
carbon dioxide, carbon monoxide and nitrogen oxides, to name a few.136 
For example, to increase yields, coca growers use highly poisonous herbicides and pesticides; processors in turn use 
large quantities of harmful substances, including sulphuric acid, gasoline and kerosene, which they discard onto 
the ground and into waterways.137 In parts of Latin America, aerial fumigation has aff ected legal crop plantations, 
forests, rare plants, water sources and other sites not targeted by fumigation campaigns.138 In parts of Asia, an 
aerial eradication campaign using the herbicide 2, 4-D, a major ingredient in Agent Orange, reportedly destroyed 
villagers’ crops and livestock.139 In some instances, evidence has shown that aerial fumigation campaigns have not 
eradicated illicit production but, rather, displaced it to new areas of greater environmental signifi cance.140 A similar 
‘balloon eff ect’ has been found for manual and aerial eradication in the Andean region.141 
Eff orts to destroy illicit crops have encouraged growers to move to remote areas with little state presence, far from 
urban centres and with little infrastructure, including national parks and protected forest areas. Aerial fumigation 
campaigns in Colombia and government pressure to reduce coca cultivation in Bolivia and Peru have pushed 
growers to clear new plots in national parks and protected forest areas, increasing deforestation and threatening 
biodiversity.142
Glyphosate, a herbicide used in aerial fumigation of illicit coca crops, has been associated with serious harm to 
physical and mental health, food security, family income and the environment.143 The International Agency for 
Research on Cancer, a specialized WHO agency, recently reclassifi ed glyphosate as a probable carcinogen.144 UN 
experts in the rights of children, health and indigenous people have also raised concerns about the negative eff ects 
on the health and environment of aerial spraying with glyphosate, noting particular concern with its eff ects on the 
most vulnerable and marginalized people.145 Ecuador has also fi led complaints with the Permanent Council of the 
Organisation of American States and the International Court of Justice about the harmful eff ects of aerial spraying 
within its territory.146 
Drug-traffi  cking and -marketing activities also harm the environment. In transit areas of Central America, drug 
traffi  ckers have built landing strips in protected forest reserves for aircraft transporting illicit drugs, and have 
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converted forests and other areas of high ecological value to agriculture, often cattle ranches and palm oil 
plantations, to launder drug money.147
2.8 Impact of drug control policies on indigenous people and 
  traditional and religious practices
The 1961 Single Convention on Narcotic Drugs imposed special restrictions 
on the cultivation of coca, opium and cannabis for indigenous, traditional 
and religious uses, and required that such use be abolished within 15 
years for opium smoking, 25 years for coca leaf chewing and as soon 
as possible but no later than 25 years for cannabis (article 49(2)).148 The 
1988 Convention against Illicit Traffi  c in Narcotic Drugs requires States to 
criminalize the possession, purchase and cultivation of coca for personal 
consumption contrary to the provisions of the 1961 Convention, and to 
take measures to prevent cultivation of and to eradicate illicit crops. In 
doing so, States must “take due account of traditional licit uses, where 
there is historic evidence of such use” (article 14(2)).149
Woman selling coca leaves in Bolivia, Julie Laurent 
“Spraying the crops just penalizes 
the farmer and they grow the crops 
somewhere else. ...This is the least 
eff ective program ever.” 
Richard Holbrooke, US Special Envoy to 
Afghanistan and Pakistan, 2002 
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The criminalization of indigenous, traditional practices done without consultation with indigenous communities 
raises a number of human rights and development concerns. The ban on traditional uses of coca, opium and 
cannabis in the 1961 Convention was passed at a time when scant attention was given to cultural and indigenous 
rights. Since then, key international instruments and relevant jurisprudence have been adopted that protect the 
right of all indigenous peoples to free and prior informed consent relating to issues that aff ect them, to maintain 
traditional, religious and medical practices and to own, develop, control and use their real property and resources.150 
The criminalization of drugs used for traditional and religious purposes is in misalignment with human rights 
protections for the traditional and religious uses of controlled drugs.151
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As described in Chapter 2, current drug control policies aff ect many aspects of UNDP’s work. UNDP is present in 170 
countries, working to help countries eradicate poverty, eliminate inequalities and foster inclusion. In this context, 
UNDP has an important opportunity to support countries to adopt evidence-based and development-sensitive 
drug policies that address the harms caused by illicit drug production, traffi  cking and abuse, as well as the harm 
caused by drug control eff orts. However, this requires, among other things, focusing not only on illicit cultivation 
and use but also on their root causes: poverty, social exclusion, inequality, government instability and weak rule of 
law. Table 2 provides a snapshot of how drug policy intersects with various aspects of UNDP’s work as articulated 
in its ‘Strategic Plan 2014–2017’. 
Table 2.  How drug policy intersects with UNDP’s work
UNDP Strategic Plan
Outcomes
Examples of issues related to drug policy that negatively aff ect the 
achievement of UNDP Strategic Plan Outcomes
1 Growth and 
development 
are inclusive 
and sustainable, 
incorporating productive 
capacities that create 
employment and 
livelihoods for the poor 
and excluded
 Inhibition of legitimate social and economic activity and a lack of 
formal and legal economic alternatives for poor people, youth, women, 
indigenous populations and other excluded groups, because of illegal 
market dynamics
 Forced eradication campaigns precede development of alternative 
livelihood options, undermining food security and exacerbating poverty 
 Greater exposure to risks in areas with high poverty rates due to a mix 
of social determinants such as higher availability of drugs and arms, 
higher urbanization levels, higher crime rates, presence of traffi  cking 
organizations, repressive law enforcement strategies and presence of 
violence
2 Citizen expectations 
for voice, development, 
the rule of law and 
accountability are met 
by stronger systems of 
democratic governance
 Excessive use of criminal justice mechanisms, the disproportionality 
of penalties for drug off ences, including the death penalty and long-
term incarceration, abuse of pre-trial detention and the enforcement 
of mandatory sentencing laws contribute to overload the judicial and 
prison systems, making them even more ineffi  cient and undermining 
people’s confi dence in them
 Impunity for human right abuses and major crimes due to corruption of 
and major threats to justice system offi  cials and other decision makers 
and administrative authorities
 Erosion of democratic governance, rule of law and people’s adherence 
to social norms and institutions by illegal actors or by means of the 
‘normalization’ of illegal activities, political and economic infl uence or lack 
of protection from law enforcement and justice
3. SUSTAINABLE DEVELOPMENT 
 APPROACHES TO DRUG POLICY
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UNDP Strategic Plan
Outcomes
Examples of issues related to drug policy that negatively aff ect the 
achievement of UNDP Strategic Plan Outcomes
3 Countries have 
strengthened 
institutions to 
progressively deliver 
universal access to basic 
services
 Discrimination, a lack of investment in health and social welfare and laws 
criminalizing drug use/possession of small amounts of drugs for personal 
use impede the access of people who use drugs to basic services such 
as housing, education, health care, employment, social protection and 
treatment
 Lack of social (re)integration processes along with signifi cant 
percentages of relapses and readmissions limit the chances of 
addressing drug dependence and substantially reduce the effi  ciency of 
investments in treatment and recovery systems 
 The absence of comprehensive harm reduction and eff ective prevention, 
treatment and care services and policies for people who use drugs 
contributes to increased prevalence of HIV and other infectious diseases 
4 Faster progress is 
achieved in reducing 
gender inequality and 
promoting women’s 
empowerment
 Involvement of women in drug trading due to economic and gender 
inequality, such as single mothers needing a means by which to support 
their family
 Disproportionate incarceration of women for their participation 
in the lowest levels of drug production or traffi  cking. Women feel 
consequences of criminal punishment diff erently, often with greater 
impact on their children and families. Lack of drug-related services for 
women who use drugs in prison or pre-trial detention
 Higher risk of violence and abuse, with gender-specifi c stigma and 
discrimination intersecting with and exacerbating that faced by people 
who use drugs 
5 Countries are able to 
reduce the likelihood of 
confl ict, and lower the 
risk of natural disasters, 
including from climate 
change
 Weak States enable environments conducive to illicit activity, thereby 
allowing armed groups to use illicit drug economies to fi nance their 
activities, thus threatening citizen security and fuelling confl ict
 Implementation of repressive drug control policy causes loss of 
livelihoods, displacement, migration and criminalization of rural 
communities, fuelling confl ict
 Deforestation, land degradation, loss of endemic species and pollution of 
aquifers from illegal production of drugs or the fumigation, eradication 
and destruction of drug laboratories
6 Early recovery and rapid 
return to sustainable 
development pathways 
are achieved in post-
confl ict and post-
disaster settings
 Violent confl icts cause considerable damage to infrastructure, 
destroy livestock and farming land, result in the mass displacement 
of populations, lead to social instability, loss of household members, 
and human rights violations, and undermine human development. 
Participation in the illicit drugs economy becomes a viable source of 
income
 Loss of income, unemployment and food insecurity resulting from 
supply control programmes may lead to frustration, antipathy towards 
authorities and social instability. Experiencing hardship and with no other 
options on hand, households often resume cultivation of drug crops, and 
farmers disperse fi elds more widely or move to more remote locations
 Economic turbulence, along with poverty and social inequality, can also 
exacerbate existing obstacles in access to health, education and social 
services
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UNDP Strategic Plan
Outcomes
Examples of issues related to drug policy that negatively aff ect the 
achievement of UNDP Strategic Plan Outcomes
7 Development debates 
and actions at all levels 
prioritize poverty, 
inequality and 
exclusion, consistent 
with our engagement 
principles
 Pre-eminence of prohibition and abstinence-based policies fuel 
exclusion and do not allow for debate on the eff ects of drugs and drug 
policy on poor and excluded populations
 High sensitivity of drug issues along electoral processes, generating 
political problems for the promotion and approval of alternative policies 
and interventions
 Metrics for drug policy success are based on the specifi c and narrow 
traditional objectives of reducing drug demand and supply without any 
other consideration of its impact on human rights, social inclusion or on 
any other elements of sustainable human development
3.1 Development-sensitive policy and programming 
Many aspects of UNDP’s policy and programme work in countries could support initiatives already being undertaken 
by UN Member States to implement development-sensitive drug control policies that contribute to reducing drug-
related harms. 
3.1.1 Sustainable development pathways
A substantial body of evidence has shown that drug policies anchored in economic and social development plans 
are more likely to result in positive development outcomes. An important opportunity exists for UNDP to support 
Member States’ programmes to tackle poverty, inequality and exclusion in a way that empowers vulnerable 
populations who depend on illicit drug economies or those who experience exclusion because of problematic 
drug use. UNDP’s sustainable human development-based interventions can improve the development outcomes 
of poor urban, peri-urban and rural communities and boost their prospects for employment and livelihoods, 
off ering strong connections to issues of environmental sustainability, governance and resilience. UNDP also has 
experience in addressing complex development issues with wide-ranging social, economic and environmental 
impacts ranging from HIV, combating deforestation caused by expanding cultivation of illicit crops, and violence 
and human rights abuses resulting from drug-traffi  cking or repressive drug control policies. UNDP’s focus on 
vulnerable populations provides an important opportunity to reduce the harmful eff ects of drug policy and control 
on the most vulnerable. 
UNDP’s work on improving access to natural resources essential for employment and livelihoods, integrating 
sustainable land, water and forest management, as well as measures related to conservation and sustainable use 
of biodiversity into the mainstream of development policy and decision-making, will be an important reference 
to register success for aff ected populations and geographic areas. Key interventions, such as supporting countries 
with the reform of legal and regulatory frameworks so that the poor, indigenous populations and local communities 
can have secure access to natural resources, and to a fair and equitable distribution of benefi ts arising from the 
sustainable use of biodiversity and ecosystem services, might have strong infl uence in overcoming dependence 
on drug-producing and -traffi  cking economies.
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3.1.2 Inclusive and eff ective democratic governance
UNDP’s work assisting countries to maintain or secure peaceful and democratic governance, helping institutions 
to adapt to changing public expectations and deliver clear benefi ts to citizens, whether in terms of better services, 
improved access to resources needed for employment and livelihoods or greater security, could also provide an 
important pathway into the development of evidence-informed drug policies anchored in human rights principles. 
Promoting accountability, inclusive governance and participation reduces space for corruption and infi ltration of 
government institutions by organized crime.152 
Many UN Member States are facing great challenges to eff ectively address the negative impacts of drug use and 
drug policy. UNDP’s experience in the design and implementation of evidence-based, sustainable human 
development-oriented public policy has strong potential for helping drug policy frameworks bring greater 
development benefi ts to citizens and increased confi dence and trust in public institutions, both at national and at 
subnational levels. UNDP’s work in reinforcing the rule of law and citizen security should promote greater respect 
for citizen rights, facilitate stronger civilian oversight, help to counter drug-related discrimination and allow for 
faster progress in reducing drug-related gender-based violence. Moreover, UNDP’s promotion of civil, political, 
economic, cultural and social rights should help reduce the discrimination and violence experienced by women, 
youth, indigenous people and other minorities with linkages to drug use or drug markets.
UNDP could build on its experience working with Member States to review and shape laws and legal practices to 
create legal and human rights environments supportive of eff ective responses to HIV for people who use drugs and 
other marginalized populations. This work could provide a model for meaningful engagement with civil society 
and, in particular, with those most aff ected by drug-related problems to address drug laws, policies and practices 
that aff ect their lives and the communities in which they live.153 
UNDP could support longer-term eff orts to strengthen democratic governance wherever it has been challenged 
by illicit actors of drug markets—for example, on issues such as legislative oversight, transparency of public 
accounts, improvements in public administration, strengthening capacities of local governments to deliver basic 
services, and working with the non-governmental and private sectors. Furthermore, complementary support can 
be given to address justice and security-sector institutions, focusing on rapid restoration of access to justice and 
the rule of law, transitional justice measures, longer-term recovery of justice and security-sector institutions and 
the implementation of preventive strategies to confront drug-related crime and violence, including gender-based 
violence. 
3.1.3 Resilience building
All areas of work proposed in the UNDP ‘Strategic Plan 2014–2017’ can help build resilience for reducing and coping 
with the harmful impact of drug-related problems. Initiatives that result in higher levels of employment, more 
equitable access to resources, better protection against economic and environmental shocks, peaceful settlement 
of disputes, progress towards democratic governance, and comprehensive HIV and health responses that include 
harm reduction all can mitigate the negative impacts of drug production and traffi  cking and problematic drug use.
Averting major development setbacks and promoting human security in areas and communities strongly aff ected 
by violence and other threats caused by illicit drug production and traffi  cking, or by the negative consequences 
of repressive drug policies, are other aspects of people-centred human development. UNDP has experience and 
capacity to ensure eff ective recovery from confl ict-induced crises in those cases where prevention has fallen 
short, through early economic recovery and a focus on employment and livelihoods stabilization and creation, 
34  l  ADDRESSING THE DEVELOPMENT DIMENSIONS OF DRUG POLICY
reintegration of displaced persons, and restoration of basic infrastructure at the local level. Additionally, peaceful 
resolution of disputes and mediation to stabilize volatile conditions could be of great help in areas with drug 
market-related confl icts. In these contexts, interventions on illegal economies must be centred on the protection 
of citizens and the reduction of risks, harms and negative impacts.
Table 3 provides a snapshot of how UN Member States, with support from UNDP, could promote development-
sensitive policies and programmes on drug policy and control.
Table 3.  Ways to promote development-sensitive policies and programmes on drug policy and control
Resilience building Inclusive and eff ective 
democratic governance
Sustainable development 
pathways
Address mass incarceration and 
disproportionate sentencing by, 
for instance, increasing access to 
legal services and alternatives to 
incarceration
Address abuses that interfere with 
access to comprehensive harm 
reduction services, including 
laws criminalizing drug use and 
possession of small amounts of 
drugs for personal use and drug 
paraphernalia 
Support the provision of viable 
and sustainable livelihoods 
for small farmer-producers of 
illegal drug crops and ensure 
that alternative development 
programmes are non- 
discriminatory and based on 
economically realistic alternatives
Address state capacity to 
reduce the power of criminal 
organizations as well as the 
violence and insecurity that result 
from their competition with both 
one another and the State
Address legal, regulatory and 
policy barriers to access to 
narcotic drugs for pain relief 
(e.g. morphine) and drug 
treatment (e.g. methadone 
and buprenorphine for opioid 
dependence)
Advocate that illicit crop 
eradication not be undertaken 
until small-farmer households 
have been supported to adopt 
viable and sustainable livelihoods 
Promote the meaningful 
participation of communities 
including people who use drugs 
and indigenous communities 
aff ected by drug control policies 
in the development and 
implementation of policies that 
aff ect them
Take advantage of fl exibilities 
available in the drug conventions 
on penalization of possession 
and use of controlled substances, 
including decriminalization of 
drug use and possession of small 
amounts of drugs for personal use
Support local development, while 
considering interactions with 
factors such as human security, 
governance, violence, human 
rights, and food security
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4. OPPORTUNITIES TO ADDRESS DEVELOPMENT
 DIMENSIONS OF DRUG CONTROL POLICY
UNGASS 2016 and related preparatory meetings present UN Member 
States, its organizations and the international community at large with 
an opportunity to engage in a critical discussion about the development 
dimensions of current drug control policies. This discussion should consider 
the diverse impacts of drug control policy on the health and social welfare of 
individuals, the environment, governance and the rule of law. UNDP stands 
ready to support a coordinated UN response that integrates a development 
perspective into drug control strategies across the UN system, in line with 
the vision and values of the UN Charter. Potential opportunities include 
the development of metrics to evaluate the development impact of drug 
control policies, and UNDP’s engagement in eff orts to promote UN system-
wide coherence. 
4.1 New metrics to evaluate drug control 
  policies
The success of drug control eff orts has mainly been measured by specifi c 
and narrow traditional metrics of supply and demand reduction: hectares 
of illicit crops eradicated, volumes of drugs seized, and numbers of people 
arrested, convicted and incarcerated for drug law violations.154 These are 
process measures that refl ect the scale of enforcement eff orts but reveal 
very little about the impact of drug use or policies on people’s lives. They 
fail to consider their impact on human rights, social inclusion or any other 
elements of sustainable human development. As the Global Commission on 
Drug Policy has observed, “Process measures can give the impression of success, 
when the reality for people on the ground is often the opposite.”155 Measuring 
success only by arrests and seizures may create perverse incentives for law 
enforcement, and may encourage law enforcement to engage in violence 
or other abuse to achieve these goals. It can also encourage police to seek 
out small off enders, such as people who use drugs or commit minor drug-
related off ences, as they are easy targets for arrest. 
The development of a comprehensive set of metrics to measure the full 
spectrum of drug-related health issues, as well as the broader impact of drug 
control policies on human rights, security and development would be an 
important contribution to the discussion on the development dimensions 
of drug policy. UNDP’s experience with human development indices and its 
mandate to promote human development make it well suited to play a role 
in the development of such metrics. 
Possible metrics to consider include, 
for example:
 goals that address root causes that 
contribute to supply and demand for 
drugs, including poverty, food insecurity, 
lack of access to markets, health and 
education, lack of land tenure, lack of 
security, presence of armed confl ict; 
 targets that address progress towards 
ensuring the “health and welfare of 
mankind”, including a decrease in the 
number of overdose deaths and infection 
rates for HIV, hepatitis B and C and other 
communicable diseases among people 
who use drugs; an increase in access 
to harm reduction, treatment demand 
and treatment access; an increase in 
investments in health and social welfare 
benefi ts, and in the number of people 
receiving such assistance; and a reduction 
in excessive and disproportionate 
punishments; and
 indicators that measure access to 
health care information and services 
in consultation with and with the 
participation of aff ected communities; 
harms to individuals and communities, 
such as the number of victims of drug-
related violence; levels of social and 
economic development in communities 
where drug production, consumption 
or sale is concentrated; and underlying 
conditions of poverty, inequality and 
insecurity that sustain cultivation of drug 
crops and exacerbate vulnerability to 
traffi  cking and organized crime.
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4.2 Drug policy and the post-2015 agenda
In his report of December 2014, the UN Secretary-General summarizes the expectations of a diverse range of 
constituencies for the future development framework: “People across the world are looking to the United Nations to 
rise to the challenge with a truly transformative agenda that is both universal and adaptable to the conditions of each 
country, and that places people and the planet at the centre.”156
As UN Member States progress with offi  cial negotiations on the new development agenda to be adopted in 
September 2015, they are guided in their discussions to a large extent by the proposal of the Open Working Group 
(OWG) on SDGs that sets out 17 specifi c goals with 169 associated targets. 
Figure 2.  Six essential elements for delivering the SDGs 
Source: United Nations, 2014, ‘The Road to Dignity by 2030: Ending Poverty, Transforming All Lives and Protecting the Planet—Synthesis Report 
of the Secretary-General on the Post-2015 Agenda’
The proposed SDG on health which calls for ensuring healthy lives and well-being for all at all ages does include a 
specifi c target on narcotic drugs to “strengthen prevention and treatment of substance abuse, including narcotic 
drug abuse and harmful use of alcohol.” However there are some concerns among drug policy experts that the 
OWG proposal parcels drug-related issues across the diff erent goals in a way that may undermine a coherent and 
comprehensive approach to drug policy and make it more diffi  cult to evaluate the impact of drug-related issues 
on these goals.157 
Topics and principles at the core of the post-2015 agenda that cut across numerous SDGs and should be considered 
in relation to drug policy include:
  poverty eradication, sustainable consumption and production, and protection of the natural resource 
base of economic and social development;
  people-centred approaches: just, equitable and inclusive economic growth, social development and 
environmental protection to benefi t all;
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  freedom, peace and security, the rule of law, good governance, gender equality, women’s empowerment 
and commitment to just and democratic societies for development; 
  respect for the Universal Declaration of Human Rights;
  the importance of international cooperation and of common but diff erentiated responsibilities;
  the need for diff erent approaches depending on national or local circumstances and priorities;
  the need for additional resources for sustainable development; and 
  improvement of the quality, coverage and availability of disaggregated data to ensure that no one is left 
behind.
According to drug policy experts, there are contradictions between the targets established in the global 
development agenda being debated for the post-2015 period and current drug policies emanating from the three 
drug conventions. The SDGs aim to promote sustainable development, including health and well-being for all. 
However, as described above, global drug policies and their unintended consequences have fuelled and escalated 
violence; disproportionately diverted limited funds and political attention away from public health to law 
enforcement; and impeded access to lifesaving harm reduction interventions and medications essential to treat 
pain and drug dependence. 
Several SDGs aim to end poverty and hunger, protect the environment and promote sustainable livelihoods, but 
drug production and traffi  cking, and related law enforcement activities, degrade the environment by contaminating 
water and soil and harming protected forests. 
A number of SDGs aim to promote human rights by combating discrimination, promoting gender equality and 
strengthening access to justice and government accountability at all levels. However, the illicit drug trade, and 
eff orts to control it, have devastating impacts on indigenous people and on women and girls, have undermined 
democratic governance and the rule of law and threatened the human rights of people who live in communities 
where drugs are produced, through which they are traffi  cked and where they are sold. These contradictions need 
to be clearly presented and debated in the process of defi ning the new global agenda for sustainable development 
and, more intensely, during the evaluation of the international drug control system and its implementation on the 
road to UNGASS 2016.
Drug control  policy should not be a negative factor hampering the attainment of national aspirations to advance 
human development and the post-2015 development agenda more broadly; instead, it must play a positive role 
in advancing these goals and objectives. The post-2015 development agenda provides an opportunity to establish 
diff erent measures of success for drug policy, with a clear articulation of metrics related to the impact of drug 
policies on peace, development and human rights.
4.3  The road to UNGASS 2016: an opportunity to increase 
  coherence in the UN system
To date, drug control policy has largely promoted a prohibitionist, law enforcement-led and abstinence-based 
approach. This has started to change.158 UNODC has on several occasions acknowledged the ‘unintended’ negative 
consequences of drug control policies, and both UNODC and the INCB have made clear that the drug conventions 
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do not require criminalization of drug use or drug possession for personal use.159 UNODC has also acknowledged the 
role of human rights abuses against people who use drugs in fuelling HIV. It has encouraged Member States to use 
UNGASS 2016 as an opportunity to rebalance international drug control policy responses to focus more on health 
and respect for human rights and address the stigma and discrimination that limit access to services by people 
who use drugs.160 There have been calls for the greater involvement of the various UN agencies and programmes 
whose mandates and areas of work are impacted by drug policy, and this could contribute to recalibrating the 
approach to international drug policy. 
The UN Secretary-General extended the mandate of the inter-agency Task Force on Transnational Organized Crime 
and Drug Traffi  cking, co-chaired by UNODC and the UN Department of Political Aff airs, to facilitate broader input 
from all relevant UN agencies into UNGASS 2016. The Task Force has facilitated greater participation by several UN 
agencies and programmes to develop an eff ective, comprehensive, balanced and system-wide response to the 
challenge of transnational organized crime and drug traffi  cking as threats to security and stability. 
In the short term, in supporting Member States on SDG implementation and on the road to UNGASS 2016, UNDP 
could facilitate discussions between UN Member States and relevant actors, including other UN agencies, on 
various aspects of drug policy and human development, with the underlying aim of increasing attention to the 
development dimensions of drug policy. This should open up the space for the participation in global, regional and 
national debates of representatives from Member States not only belonging to law enforcement agencies or to 
the diplomatic fi eld but also to development, health, education, labour and other social sectors. Setting a specifi c 
agenda of debates and events on the road to UNGASS, considering special milestones during this period such as 
the CND high-level and inter-sessional segments, the ECOSOC Substantive Session, and other special events, is 
important for this purpose.
UNDP’s greater involvement in discussions on drug policy in the lead-up to UNGASS 2016 presents a crucial 
opportunity to emphasize the importance of an evidence-informed, people-centred and development-sensitive 
approach to drug control policy. This approach could facilitate the future defi nition of more fi t for purpose and 
balanced inter-agency coordination structures on drug-related issues within the UN, and a comprehensive and 
coherent system-wide response.
ADDRESSING THE DEVELOPMENT DIMENSIONS OF DRUG POLICY  l  39
5. CONCLUSION
UNDP’s sustainable human development mandate aff ords it the opportunity to support development-centred 
approaches and solutions, including as it relates to the intersection of drug policy and development. UNDP is 
uniquely positioned within the UN system to leverage its extensive knowledge of the similarities and diff erences 
between countries at diff erent stages of development, and to translate that into evidence-based insights for 
eff ective, adaptable development solutions, responding eff ectively to country and local demand. The wide reach 
of UNDP, its ‘lead in development thinking’, its operational focus and its relationships of trust with national partners 
are strong assets to address complexity, to deliver development results and to become a force for development-
sensitive reform in this area. 
UNDP’s greater involvement in drug policy discussions could also spur constructive engagement by other UN 
agencies and organizations while deepening strategic thinking and responses by the UN system, developing 
consistency in the formulation and monitoring of results, forging closer links between programmes and agencies 
and strengthening links with non-UN partners. UNDP’s focus on country-level coordination and on development 
results could strengthen UN Country Team capacity to support Member States’ priorities, providing assistance 
through its technical and policy expertise, and drawing on non-resident agencies with relevant knowledge and skills. 
Additionally, UNDP’s coordination with the UN Secretariat, in particular with the Department of Economic and 
Social Aff airs, the Offi  ce for the Coordination of Humanitarian Aff airs, the Department of Peacekeeping Operations 
and the Department of Political Aff airs, could contribute to enhancing development-sensitive drug policy and 
programming and support UN system coherence in this area.
UNDP’s commitment to South–South and triangular cooperation, capacity-building and facilitation of sharing 
lessons learned are important assets that could be mobilized towards supporting development-sensitive drug 
control policy and for other sustainable human development issues. UNDP could help across a range of settings to 
to build capacity and disseminate knowledge on what has worked in varying development contexts and what has 
not; work with partners to support the harmonization of policies and regulations; mobilize strategic funding and 
technical cooperation; and connect relevant actors to develop eff ective development solutions while benefi ting 
from its wide network of development partners. Adding UNDP’s engagement to the existing mix of actors could 
contribute signifi cantly to ensuring that drug policy and control eff orts are more aligned with development 
objectives.
TARGET AREAS
Knowledge on 
what has worked and 
what has not
Enabling harmonization of 
policies, legal frameworks 
and regulations
Strategic funding and 
technical cooperation from 
a variety of sources
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